Tam C. Phan, PharmD, AAHIVP, assistant professor of clinical pharmacy, USC School of Pharmacy, talks about how HIV pre-exposure prophylaxis (PrEP) therapies in the pipeline address disparities in patient access and adherence.
Tam C. Phan, PharmD, AAHIVP, assistant professor of clinical pharmacy, USC School of Pharmacy, talks about how HIV pre-exposure prophylaxis (PrEP) therapies in the pipeline address disparities in patient access and adherence.
Transcript
How do HIV PrEP therapies currently in the pipeline differ from those currently available?
I think with newer technology development, we're hoping to make PrEP more accessible and easier to adhere to. That would require and allow the patient to come in to clinic every 2 months or even, potentially in the pipeline, every 6 months, as mentioned. And that will allow for patients to have an easier access and potentially hope to also decrease some of the costs associated with current PrEP use, such as coming in quarterly for their visits or their updated testing for screenings for comorbid conditions.
If approved, how do you anticipate these will help address health disparities and patient access issues?
The population that is being impacted the most, so again Black gay men and also transgender women, typically and historically, they have been marginalized and been put at a disadvantage when it comes to their cisgender or White comparator or counterpart. So that could be associated to lower socioeconomic status, not having work, or being discriminated against in the health care setting.
Ideally, with the long-acting injectables, we can help increase access for patients because it would decrease the amount of visits they would have per year. Also, it would help highly with adherence because, currently, the medications, some of the options that we currently have for oral medications require daily administration vs in the pipeline and ideally with the injection every 2 months or every 6 months. If the product gets approved, then it would allow the patients to adhere to the medication easier.
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More